Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTPW) Gross Margin (2022 - 2025)

Historic Gross Margin for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to 22.87%.

  • 60 Degrees Pharmaceuticals' Gross Margin fell 403200.0% to 22.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.44%, marking a year-over-year increase of 14400.0%. This contributed to the annual value of 36.67% for FY2024, which is 1238200.0% up from last year.
  • As of Q3 2025, 60 Degrees Pharmaceuticals' Gross Margin stood at 22.87%, which was down 403200.0% from 50.41% recorded in Q2 2025.
  • Over the past 5 years, 60 Degrees Pharmaceuticals' Gross Margin peaked at 538.03% during Q4 2022, and registered a low of 325.81% during Q1 2023.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' median Gross Margin value was 22.89% (recorded in 2024), while the average stood at 8.41%.
  • Per our database at Business Quant, 60 Degrees Pharmaceuticals' Gross Margin plummeted by -5544100bps in 2023 and then skyrocketed by 3638900bps in 2024.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' Gross Margin stood at 538.03% in 2022, then plummeted by -103bps to 16.37% in 2023, then skyrocketed by 412bps to 51.13% in 2024, then plummeted by -145bps to 22.87% in 2025.
  • Its Gross Margin was 22.87% in Q3 2025, compared to 50.41% in Q2 2025 and 55.2% in Q1 2025.